Research spotlight: Factors contributing to treatment resistance in CAR T therapies for solid tumors
Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, “TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids”.
The study was a collaboration with the late Soldano Ferrone, MD, PhD, and was carried across the finish line by his daughter Cristina Ferrone, MD, Moshe Sade-Feldman, PhD, and several other collaborators ...









